SCHEMBL2292775

SCHEMBL2292775

COc1ncc2ccc(F)c(C(CO)CCNC(=O)OC(C)(C)C)c2n1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 2/20 0.36
ALOX5AP P20292 1/20 0.34
FEN1 P39748 1/20 0.34
ACVR1B P36896 1/20 0.34
TGFBR1 P36897 1/20 0.34
ACVRL1 P37023 1/20 0.34
STK17B O94768 1/20 0.34
STK17A Q9UEE5 1/20 0.34
CKS1B P61024 1/20 0.34
SKP1 P63208 1/20 0.34
SKP2 Q13309 1/20 0.34
MEN1 O00255 1/20 0.33
GAA P10253 1/20 0.33
KMT2A Q03164 1/20 0.33
KDM4E B2RXH2 2/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
BCHE P06276 1/20 0.32
NQO2 P16083 1/20 0.32
KCNH2 Q12809 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2289667 0.91 SCN9A (0.34) SCN9AALOX5APFEN1STK17BSTK17A
SCHEMBL1711943 0.87 MTNR1A (0.42) SCN9AMEN1GAAKMT2AKDM4E
SCHEMBL2292765 0.82 ROCK2 (0.36) SCN9AKDM4E
SCHEMBL15707804 0.80 KCNH2 (0.41) SCN9AKDM4EKCNH2TDP1
SCHEMBL2287233 0.79 SCN9A (0.34) SCN9AALOX5APFEN1KDM4EKCNH2
SCHEMBL1711953 0.78 MTNR1A (0.39) SCN9A
SCHEMBL1724180 0.71 KCNH2 (0.43) SCN9AKCNH2
SCHEMBL4797081 0.69 CKS1B (0.37) CKS1BSKP1SKP2KCNH2
SCHEMBL1712060 0.69 MTNR1A (0.40) SCN9AKDM4ENPC1RAB9AL3MBTL1
SCHEMBL1712057 0.69 PTGS2 (0.38) SCN9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8618092-B2 Tricyclic oxazolidinone antibiotic compounds ACTELION PHARMACEUTICALS LTD. (CH) 2013-12-31 US disclosed
US-20110195961-A1 TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS ACTELION PHARMACEUTICALS LTD. (CH) 2011-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195961-A1 TRICYCLIC OXAZOLIDINONE ANTIBIOTIC COMPOUNDS HRH3, OXA1L, HRH1 SCN9A 458/4885ALOX5AP 3914/4885FEN1 1470/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.